2cureX
0.552
SEK
+0.73 %
Less than 1K followers
2CUREX
First North Stockholm
Medical Equipment & Services
Health Care
Overview
Ownership
+0.73%
+41.54%
+33.98%
+30.81%
-7.23%
+30.81%
-95.83%
-95.58%
-92.74%
2cureX is a Danish-based biotech company with subsidiary in Hamburg, Germany. The company has made a special sensitivity test, IndiTreat, for oncology clinics that is focused on improving the outcome for cancer patients by improving the efficiency of the individual cancer treatment. IndiTreat uses a biopsy from the individual cancer patient to measure and predict the likely outcome of different available treatments, thereby assisting oncologists to choose the most effective treatment for the individual patient.
Read moreMarket cap
13.86M SEK
Turnover
69.56K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
26/6
2025
General meeting '25
21/8
2025
Interim report Q2'25
26/2
2026
Annual report '25
All
Press releases
3rd party
ShowingAll content types
2cureX publishes interim report for the second half year of 2024
2CUREX APPOINTS MANGOLD FONDKOMMISSION AB TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools